(107 days)
No
The device description and performance studies focus on the mechanical and biological properties of the sponges and applicator, with no mention of AI or ML. The radiopaque markers are for detection via X-ray, not for AI/ML analysis of images.
Yes
The device is intended to control severe, life-threatening bleeding and provides a temporary solution for hemorrhaging, directly addressing a health condition.
No
This device is described as a hemostatic device intended to control bleeding from wounds. While it contains radiopaque markers for detection via X-ray (a diagnostic imaging modality), the primary purpose of the device itself is not to diagnose a condition but to treat bleeding. The X-ray is used to confirm the removal of the device parts, not to diagnose the patient's medical state.
No
The device description clearly details a physical medical device composed of compressed sponges, an applicator, and a plunger, intended for direct physical application to wounds. It is not a software-only device.
Based on the provided information, the XSTAT-12 device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening. This testing is performed outside the body (in vitro).
- XSTAT-12 Function: The XSTAT-12 is a hemostatic device designed to be directly inserted into a wound to control bleeding. It works by absorbing blood and expanding within the wound. This is an in vivo (within the body) application, not an in vitro test of a specimen.
- Intended Use: The intended use clearly states "control of bleeding from wounds," which is a therapeutic action performed directly on the patient, not a diagnostic test on a sample.
- Device Description: The description focuses on the physical properties of the sponges and their mechanism of action within the wound, not on analyzing biological markers or substances in a sample.
Therefore, the XSTAT-12 falls under the category of a therapeutic medical device, specifically a hemostatic agent, rather than an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
XSTAT-12 is a hemostatic device for the control of severe, life-threatening bleeding from wounds in the groin or axilla that are not amenable to tourniquet application in adults and adolescents.
XSTAT-12 is a temporary device for use up to four (4) hours until surgical care is acquired. It should only be used for patients at high risk for immediate life-threatening bleeding from, hemodynamically significant (Advanced Trauma Life Support class 3 or 4 hemorrhagic shock), non-compressible junctional wounds, and when definitive care at an emergency care facility cannot be achieved within minutes.
XSTAT-12 is NOT indicated for use in the thorax; the pleural cavity; the mediastinum; the abdomen; the retroperitoneal space, the sacral space above the inguinal ligament; or tissues above the clavicle.
Product codes
PGZ
Device Description
The XSTAT-12 dressing is composed of a standard, regenerated cellulose medical sponge that is compressed and formed into a group of approximately 38 minisponges. Each minisponge has a height of 4-5 mm and a circular surface diameter of 9.8 mm. The minisponges absorb blood upon contact, and within approximately 20 seconds expand to their pre-compressed height of 40-50 mm. The minisponges expand only in length, not radially. Each minisponge absorbs approximately 3 mL of blood. Each minisponge contains a radiopaque marker for easy detection via X-ray. The XSTAT-12 dressing includes an applicator and plunger that facilitate delivery of the minisponges to external bleeding wounds. Individual applicators are filled with the STAT-12 minisponges and are packaged in a vacuum-sealed foil pouch with one (1) plunger, terminally sterilized by gamma radiation to a sterility assurance level of 10°. The inner pouches are then packaged inside a larger outer pouch, along with one (1) casualty card and one (1) package insert. The Instructions for Use (IFU) are affixed to the outer pouch.
For the treatment of severe. life-threatening bleeding from pelvis or shoulder wounds not amenable to tourniquet application, the XSTAT-12 sponges are applied to the applicator. Once applied to the wound, the XSTAT-12 sponges absorb blood and expand, thereby packing the wound. All minisponges must be removed from wounds before surgical repair and closure of the wounds. Following removal of the minisponges and definitive surgical repair of the wound, a radiograph is required prior to wound closure to confirm that every minisponge has been removed.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
groin or axilla, junctional wounds. NOT indicated for use in: the thorax; the pleural cavity; the mediastinum; the abdomen; the retroperitoneal space, the sacral space above the inguinal ligament; or tissues above the clavicle.
Indicated Patient Age Range
adults and adolescents
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Mechanical Testing: Mechanical testing was completed on the XSTAT-12 applicator to verify the safety and efficacy of the XSTAT-12 applicator design when used in expected use scenarios, as well as in extreme temperature conditions.
Tests performed: Deployment Force Testing, Plunger Axial Force Testing, Tip Tensile Strength Testing, Fluid Immersion Testing, Wound Volume Testing.
The STAT-12 minisponges are identical to the predicate device. Thus the testing defined in the Special Controls (as per 21 CFR 878.4452) related to minisponges (radiopacity, immunogenicity, absorption capacity, extent of swelling, expansion force/pressure and viral inactivation testing for animal-derived materials) has been demonstrated by the premarket clearance of the predicate device (K152624 and reference device DEN130016/K130218). Mechanical test results demonstrated the safety and efficacy of the XSTAT-12 applicator and device.
Biocompatibility Testing: The biocompatibility evaluation for the XSTAT-12 device was conducted in accordance with the FDA Blue Book Memorandum #G95-1 and International Standard ISO 10993-1. The XSTAT-12 is an external communicating, limited duration (≤ 24 hour) contact device with potential for contact with tissue and/or bone, and indirect contact with circulating blood.
Tests performed: Cytotoxicity, Sensitization, Irritation, System Toxicity, Hemocompatibility.
The biocompatibility of the XSTAT-12 applicator was demonstrated per ISO 10993 for external communicating, limited duration (≤ 24 hour), blood-contacting devices. The XSTAT-12 minisponges are identical to the predicate device. Thus the biocompatibility testing of the XSTAT-12 minisponges has been demonstrated per ISO 10993 by the premarket clearance of the predicate device (K152624, reference device DEN130016/K130218).
Animal Study: The XSTAT-12 minisponges are identical to the predicate device. Thus the animal performance testing of the XSTAT-12 (as per 21 CFR 878.4452) has been demonstrated by the premarket clearance of the predicate device (K152624, reference device DEN130016/K130218).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4452 Nonabsorbable expandable hemostatic sponge for temporary internal use.
(a)
Identification. A nonabsorbable expandable hemostatic sponge for temporary internal use is a prescription device intended to be placed temporarily into junctional, non-compressible wounds, which are not amenable to tourniquet use, to control bleeding until surgical care is acquired. The sponges expand upon contact with blood to fill the wound cavity and provide a physical barrier and pressure that facilitates formation of a clot. The device consists of sterile, nonabsorbable radiopaque compressed sponges and may include an applicator to facilitate delivery into a wound.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Performance data must demonstrate the biocompatibility of patient-contacting components.
(2) Performance data must demonstrate the sterility of patient-contacting components including endotoxin and pyrogenicity assessments.
(3) Performance data must support device stability by demonstrating continued sterility of the patient-contacting components of the device, package integrity, and device functionality over the requested shelf life.
(4) Assessment of material characteristics must be sufficient to support safety under anticipated conditions of use. Assessments must include the following:
(i) Material specifications.
(ii) Immunogenicity.
(iii) Viral inactivation for animal-derived materials.
(5) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Absorption capacity.
(ii) Extent of swelling.
(iii) Mechanical properties.
(iv) Expansion force/pressure.
(v) Radiopacity.
(vi) Deployment/applicator functionality.
(6) In vivo performance data must demonstrate safe and effective use by verifying that the device performs as intended under anticipated conditions of use. Appropriate analysis/testing must demonstrate that the product: Controls bleeding, does not promote adverse local or systemic effects, and can be completely removed from the wound. The following performance characteristics must be tested:
(i) Deployment.
(ii) Control of bleeding.
(iii) Radiopacity.
(iv) Retrieval.
(v) Assessment of local and systemic effects.
(7) Human factors testing and analysis must validate that the device design and labeling are sufficient for appropriate use by emergency responders deploying the device as well as surgeons retrieving the device from wounds.
(8) Labeling must include:
(i) Specific instructions for deployment by emergency responders and retrieval by surgeons.
(ii) Warnings, cautions, and limitations needed for safe use of the device.
(iii) Information on how the device operates and the typical course of treatment.
(iv) A detailed summary of the in vivo and human factors testing pertinent to use of the device.
(v) Appropriate imaging information to ensure complete retrieval of device.
(vi) An expiration date/shelf life.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized design of three human profiles facing right, with flowing lines representing hair or clothing.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
July 28, 2016
RevMedx, Inc. Ms. Amy K. Pointer Director of RA/OA 25999 SW Canyon Creek Road Suite C Wilsonville, Oregon 97070
Re: K161020 Trade/Device Name: XSTAT-12, 3-pack, XSTAT-12, 1-pack Regulation Number: 21 CFR 878.4452 Regulation Name: Non-Absorbable, Exapandable, Hemostatic Sponge For Temporary Internal Use Regulatory Class: Class II Product Code: PGZ Dated: June 23, 2016 Received: June 27, 2016
Dear Ms. Pointer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
David Krause -S
for Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement on last page
510(k) Number (if known)
Device Name
XSTAT-12
Indications for Use (Describe)
XSTAT-12 is a hemostatic device for the control of severe, life-threatening bleeding from wounds in the groin or axilla that are not amenable to tourniquet application in adults and adolescents.
XSTAT-12 is a temporary device for use up to four (4) hours until surgical care is acquired. It should only be used for patients at high risk for immediate life-threatening bleeding from, hemodynamically significant (Advanced Trauma Life Support class 3 or 4 hemorrhagic shock), non-compressible junctional wounds, and when definitive care at an emergency care facility cannot be achieved within minutes.
XSTAT-12 is NOT indicated for use in the thorax; the pleural cavity; the mediastinum; the abdomen; the retroperitoneal space, the sacral space above the inguinal ligament; or tissues above the clavicle.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.qov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY RevMedx, Inc. XSTAT-12
Manufacturer Information:
RevMedx, Inc. 25999 SW Canyon Creek Road, Suite C Wilsonville. OR 97070 Phone: 503-218-2172 Facsimile: 503-218-2274 Contact Person: Amy K. Pointer, RA/QA Manager Date Prepared: 04/06/2016
Trade/Proprietary Name: XSTAT-12
Classification Name: Non-Absorbable, Expandable, Hemostatic Sponge for Temporary Internal Use
Product Classification & Code: 21 CFR 878.4452; PGZ, Class II
Predicate Devices:
XSTAT 30 (K152624)
Reference Device: XSTAT (DEN130016/K130218)
Intended Use / Indications for Use:
Intended Use:
The XSTAT-12 is intended for the control of bleeding from wounds in the groin or axilla that are not amenable to tourniquet application in adults and adolescents.
Indications for Use:
XSTAT-12 is a hemostatic device for the control of severe, life-threatening bleeding from junctional wounds in the groin or axilla not amenable to tourniquet application in adults and adolescents.
XSTAT-12 is a temporary device for use up to four (4) hours until surgical care is acquired. It should only be used for patients at high risk for immediate life-threatening from, hemodynamically significant (Advanced Trauma Life Support class 3 or 4 hemorrhagic shock), non-compressible junctional wounds, and when definitive care at an emergency care facility cannot be achieved within minutes.
XSTAT-12 is NOT indicated for use in: the thorax; the pleural cavity; the mediastinum; the abdomen; the retroperitoneal space; the sacral space above the inquinal ligament; or tissues above the clavicle.
4
Device Description
The XSTAT-12 dressing is composed of a standard, regenerated cellulose medical sponge that is compressed and formed into a group of approximately 38 minisponges. Each minisponge has a height of 4-5 mm and a circular surface diameter of 9.8 mm. The minisponges absorb blood upon contact, and within approximately 20 seconds expand to their pre-compressed height of 40-50 mm. The minisponges expand only in length, not radially. Each minisponge absorbs approximately 3 mL of blood. Each minisponge contains a radiopaque marker for easy detection via X-ray. The XSTAT-12 dressing includes an applicator and plunger that facilitate delivery of the minisponges to external bleeding wounds. Individual applicators are filled with the STAT-12 minisponges and are packaged in a vacuum-sealed foil pouch with one (1) plunger, terminally sterilized by gamma radiation to a sterility assurance level of 10°. The inner pouches are then packaged inside a larger outer pouch, along with one (1) casualty card and one (1) package insert. The Instructions for Use (IFU) are affixed to the outer pouch.
For the treatment of severe. life-threatening bleeding from pelvis or shoulder wounds not amenable to tourniquet application, the XSTAT-12 sponges are applied to the applicator. Once applied to the wound, the XSTAT-12 sponges absorb blood and expand, thereby packing the wound. All minisponges must be removed from wounds before surgical repair and closure of the wounds. Following removal of the minisponges and definitive surgical repair of the wound, a radiograph is required prior to wound closure to confirm that every minisponge has been removed.
Performance Data
The following performance data were provided in support of the substantial equivalence determination and as required per 21 CFR 878.4452.
Mechanical Testing
Mechanical testing was completed on the XSTAT-12 applicator to verify the safety and efficacy of the XSTAT-12 applicator design when used in expected use scenarios, as well as in extreme temperature conditions.
The following mechanical tests were performed and demonstrated the safety and efficacy of the XSTAT-12 applicator and device:
- Deployment Force Testing o
- Plunger Axial Force Testing o
- Tip Tensile Strenath Testing o
- Fluid Immersion Testing O
- Wound Volume Testing O
The STAT-12 minisponges are identical to the predicate device. Thus the testing defined in the Special Controls (as per 21 CFR 878.4452) related to minisponges (radiopacity, immunogenicity, absorption capacity, extent of swelling, expansion force/pressure and viral inactivation testing for animal-derived materials) has been demonstrated by the premarket clearance of the predicate device (K152624 and reference device DEN130016/K130218). The testing provided in the cleared XSTAT 30 notification (K152624) is incorporated herein by reference.
Biocompatibility Testing
The biocompatibility evaluation for the XSTAT-12 device was conducted in accordance with the FDA Blue Book Memorandum #G95-1 "Use of International Standard ISO-10993. 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing," May 1, 1995, and International Standard ISO 10993-1 "Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing within a Risk Management Process," as recognized by FDA. The XSTAT-12 is an external communicating, limited duration (≤ 24 hour) contact device with potential for contact with tissue and/or bone, and indirect contact with circulating blood.
5
The battery of testing included the following tests:
- Cytotoxicity O
- o Sensitization
- Irritation o
- System Toxicity o
- Hemocompatibilitv O
The biocompatibility of the XSTAT-12 applicator was demonstrated per ISO 10993 for external communicating, limited duration (≤ 24 hour), blood-contacting devices.
The XSTAT-12 minisponges are identical to the predicate device. Thus the biocompatibility testing (as per 21 CFR 878.4452) of the XSTAT-12 minisponges has been demonstrated per ISO 10993 by the premarket clearance of the predicate device (K152624. reference device DEN130016/K130218). The testing provided in the cleared XSTAT 30 notification (K152624) is incorporated herein by reference.
Animal Study
The XSTAT-12 minisponges are identical to the predicate device. Thus the animal performance testing of the XSTAT-12 (as per 21 CFR 878.4452) has been demonstrated by the premarket clearance of the predicate device (K152624, reference device DEN130016/K130218). The testing provided in the cleared XSTAT 30 notification (K152624) is incorporated herein by reference.
Substantial Equivalence
The XSTAT-12 is as safe and effective as the XSTAT-12 and XSTAT-12 and XSTAT 30 have the same intended use and indications for use, similar principles of operation and similar technological characteristics. There are no differences to the minisponges used in XSTAT-12 as compared to XSTAT 30, with the quantity of sponges per applicator being the only difference. The differences between the XSTAT-12 and XSTAT 30 predicate device do not present any new issues of safety or effectiveness because the use of a smaller applicator design with fewer minisponges raises the same questions of safety and effectiveness as the predicate device. The minor differences in the applicator are based upon a similar, svringe-like design to aid in the delivery of the XSTAT minisponges to the wound, but with a smaller diameter to allow XSTAT minisponges to be used in smaller diameter wounds. Thus, the XSTAT-12 is substantially equivalent to the XSTAT 30.
Conclusions
The XSTAT-12 is as safe and effective as the predicate XSTAT 30 device. The intended use and indications for use are the same for both XSTAT-12 and XSTAT 30, with similar principles of operation and similar technological characteristics. The Substantial Equivalence Summary table below details and compares the XSTAT-12 to the XSTAT 30.
6
| Characteristic | XSTAT-12 - New | XSTAT 30 - Predicate
(K152624) |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Intended Use | XSTAT-12 is intended for the control
of bleeding from wounds in the groin
or axilla that are not amenable to
tourniquet application in adults and
adolescents. | XSTAT 30 is intended for the control
of bleeding from wounds in the groin
or axilla that are not amenable to
tourniquet application in adults and
adolescents. |
| Indications for Use | XSTAT-12 is a hemostatic device for
the control of severe, life-threatening
bleeding from junctional wounds in
the groin or axilla not amenable to
tourniquet application in adults and
adolescents.
XSTAT-12 is a temporary device for
use up to four (4) hours until surgical
care is acquired. It should only be
used for patients at high risk for
immediate life-threatening bleeding
from, hemodynamically significant
(Advanced Trauma Life Support
class 3 or 4 hemorrhagic shock),
non-compressible junctional
wounds, and when definitive care at
an emergency care facility cannot be
achieved within minutes.
XSTAT-12 is NOT indicated for use
in: the thorax; the pleural cavity; the
mediastinum; the abdomen; the
retroperitoneal space, the sacral
space above the inguinal ligament;
or tissues above the clavicle. | XSTAT 30 is a hemostatic device for
the control of severe, life-threatening
bleeding from junctional wounds in
the groin or axilla not amenable to
tourniquet application in adults and
adolescents.
XSTAT 30 is a temporary device for
use up to four (4) hours until surgical
care is acquired. It should only be
used for patients at high risk for
immediate life-threatening bleeding
from, hemodynamically significant
(Advanced Trauma Life Support
class 3 or 4 hemorrhagic shock),
non-compressible junctional wounds,
and when definitive care at an
emergency care facility cannot be
achieved within minutes.
XSTAT 30 NOT indicated for use in:
the thorax; the pleural cavity; the
mediastinum; the abdomen; the
retroperitoneal space, the sacral
space above the inguinal ligament;
or tissues above the clavicle. |
| User Population | Civilian and battlefield patients | Civilian and Battlefield patients |
| Technological
Characteristics | 1. Minisponges
2. Applicator
3. Insert/Casualty Card
4. Packaging | 1. Minisponges
2. Applicator
3. Insert/Casualty Card
4. Packaging |
| Dimensions (l x w x h) | 3-Pack: 292mm x 171mm x 19mm
1-Pack: 292mm x 171mm x 19mm | 3-Pack: 254mm x 165mm x 38mm
1-Pack: 254mm x 165mm x 38mm |
| Weight | 3- Pack: 0.123kg
1-Pack: 0.055kg | 3- Pack: 0.25kg
1-Pack: 0.1kg |
| Safety Features | Radiopaque marker | Radiopaque marker |
| Biocompatibility | Cytotoxicity (ISO 10993-5);
Sensitization (ISO 10993-10);
Irritation (ISO 10993-10);
Acute systemic toxicity (ISO 10993-
11); and
Hemocompatibility (ISO 10993-4) | Cytotoxicity (ISO 10993-5);
Sensitization (ISO 10993-10);
Irritation (ISO 10993-10);
Acute systemic toxicity (ISO 10993-
11); and
Hemocompatibility (ISO 10993-4) |
| Sterilization | Gamma radiation sterilization | Gamma radiation sterilization |